ArticleHead and neck pathology2012
Mucosal pigmentation caused by imatinib: report of three cases.
Article in Head and neck pathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review.Clinical oral investigations · 2019Pooled it
- Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.Journal of the American Academy of Dermatology · 2017Pooled it
- Pigmentary Changes Reported with Tyrosine Kinase Inhibitors: A Narrative Review of Mechanisms and Clinical Implications.Clinical drug investigation · 2026Review
- Imatinib-induced hard palate mucosal discoloration in patients with gastrointestinal stromal tumour (GIST) and dermatofibrosarcoma protuberans (DFSP): a case series of three patients and literature review.Postepy dermatologii i alergologii · 2024Article
- Imatinib-induced hyperpigmentation.JAAD case reports · 2024Article
- Pathogenesis of Oral Toxicities Associated with Targeted Therapy and Immunotherapy.International journal of molecular sciences · 2023Review
- Oral hyperpigmentation associated with hydroxyurea in a patient with polycythemia vera: A case report.Clinical case reports · 2020Article
- Medication-Induced Oral Hyperpigmentation: A Systematic Review.Patient preference and adherence · 2020Review
- Imatinib-related hyperpigmentation of oral mucosa: Case report and literature review.Journal of dental sciences · 2019Article
- Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib.Maxillofacial plastic and reconstructive surgery · 2017Article
- Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Review
- Mucosal pigmentation of the hard palate in a patient taking imatinib.BMJ case reports · 2015Article
- A Rare Case of Melanosis of the Hard Palate Mucosa in a Patient with Chronic Myeloid Leukemia.Case reports in dentistry · 2015Article
- Imatinib-induced Melasma-like Pigmentation.Indian journal of dermatologyArticle
- Cutaneous complications of molecular targeted therapy used in oncology.Journal of medicine and lifeReview
- Pigmentation of the Tongue with Lapatinib Treatment in a Patient with Advanced Breast Cancer: A Case Report.Cancer treatment communicationsArticle
- Imatinib-induced Extensive Hyperpigmentation in a Case of Chronic Myeloid Leukemia.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Imatinib mesylate (STI-571, Gleevec(®)), a tyrosine kinase inhibitor, is a first-line medication for treating chronic myeloid leukemia (CML). Clinical studies revealed very good hematological responses without significant side effects. However, imatinib may lead to mucosal pigmentation. Three patients, two males aged 64 and 53 and one female aged 29 presented with a painless, diffuse, grey-blue pigmentation of the mucosa of the hard palate. Both male patients had a history of CML and had been on imatinib for 4 and 10 years, respectively. The female patient had been on imatinib for 4 years for pelvic fibromatosis. Histopathologically, deposition of fine, dark-brown, spherical granules was noted within the connective tissue. There was no inflammation or hemorrhage, and no melanosis or melanocytic hyperplasia in the epithelium. The granules stained positively for both Fontana-Masson and Prussian blue stains. Imatinib-induced pigmentation is similar to that caused by other medications such as minocycline and anti-malarial medications, namely the deposition of a drug metabolite containing melanin and iron.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.